Lemtrada and Embolex drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lemtrada (alemtuzumab) and Embolex (dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride). Common drug interactions include blood pressure increased among females.

The phase IV clinical study analyzes what interactions people have when they take Lemtrada and Embolex. It is created by eHealthMe based on reports of 27 people who take the same drugs from the FDA, and is updated regularly.

What is Lemtrada?

Lemtrada has active ingredients of alemtuzumab. eHealthMe is studying from 8,317 Lemtrada users. Check the latest studies of Lemtrada.

What is Embolex?

Embolex has active ingredients of dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride. eHealthMe is studying from 1,161 Embolex users. Check the latest studies of Embolex.



On Jul, 06, 2026

27 people who take Lemtrada and Embolex together, and have interactions are studied.

Lemtrada and Embolex drug interactions.

What are the common drug interactions of Lemtrada and Embolex, by gender? *:

female:

  1. Blood pressure increased
  2. Vomiting
  3. Blood disorder
  4. Brain death
  5. Cerebral hypoperfusion (a condition in which the brain doesn't get enough blood)
  6. Chronic fatigue syndrome (disorder that causes extreme fatigue)
  7. Cytokine storm (over-protective immune response that can actually be fatal)
  8. Feeling hot
  9. Hydrocephalus (water on the brain)
  10. Intracranial pressure increased (high pressure inside the skull and thus in the brain tissue and cerebrospinal fluid)

male:

n/a

What are the common drug interactions of Lemtrada and Embolex, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Bradycardia (abnormally slow heart action)
  2. Cerebral haemorrhage (bleeding within the brain)
  3. Seizure (abnormal excessive or synchronous neuronal activity in the brain)
  4. Vomiting
  5. Hypertension (high blood pressure)
  6. Nausea (feeling of having an urge to vomit)
  7. Loss of consciousness
  8. Acute disseminated encephalomyelitis (acute intense attack of inflammation (swelling) in the brain and spinal cord)
  9. Blood disorder
  10. Brain death

40-49:

  1. Cough
  2. Heart rate increased
  3. Blood urea increased
  4. Chest discomfort
  5. Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
  6. Creatinine renal clearance decreased
  7. Depression
  8. Dry skin
  9. Dyspnoea exertional (breathlessness or shortness of breath)
  10. Fatigue (feeling of tiredness)

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

  1. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 26 people, 96.30%
  2. Urinary Tract Infection: 13 people, 48.15%
  3. Urge Incontinence (urinary incontinence): 11 people, 40.74%
  4. Nausea (feeling of having an urge to vomit): 11 people, 40.74%
  5. Musculoskeletal Pain (pain affects the bones, muscles, ligaments, tendons, and nerves): 11 people, 40.74%
  6. Blood Pressure Abnormal: 11 people, 40.74%
  7. Birth Control: 10 people, 37.04%

* Approximation only. Some reports may have incomplete information.

Do you take Lemtrada and Embolex?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Lemtrada and Embolex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lemtrada:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Embolex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lemtrada and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Embolex and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on alemtuzumab and dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride (the active ingredients of Lemtrada and Embolex, respectively), and Lemtrada and Embolex (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: